

Clanotech granted Orphan Drug Designation by the U.S. FDA

STOCKHOLM - March 27, 2015. Karolinska Development AB (STO: KDEV), a leading Nordic investor in life sciences, today notes that the portfolio company Clanotech AB has received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its candidate drug CLT-288643 for the use as adjuvant treatment to surgery in glaucoma patients.

Clanotech's lead compound CLT-28643, an $\alpha 5\beta 1$ -integrin antagonist, has anti-angiogenic, anti-fibrotic and anti-inflammatory properties. Based on promising preclinical data in animal models for glaucoma, CLT-28643 has the potential to regulate wound healing processes following glaucoma surgery.

"Clanotech is focused on an important therapeutic area as incorrect healing after surgical intervention of glaucoma often is detrimental to maintaining vision. Karolinska Development is a dedicated investor that is focused on innovative treatments that address unmet medical needs and the received orphan drug designation confirms Clanotech's strategically fit in our portfolio", says Jim Van heusden, CEO of Karolinska Development.

For more information on the Orphan Drug Designation and Clanotech please visit: www.clanotech.se

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB

Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. For more information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX (STO: KDEV). Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.